Long-term effects of tirzepatide. - Reddit

What do the multi-year tirzepatide trials show?

The SURMOUNT-1 trial, which ran for 72 weeks (roughly 18 months), remains the largest and most cited randomized controlled trial of tirzepatide for weight management. Participants in the 15 mg arm achieved an average of approximately 21% body weight reduction by week 72, with weight loss continuing to progress through the end of the trial rather than plateauing early.

SURMOUNT-4 extended the evidence base by examining what happens when people who had already lost weight on tirzepatide were randomized to either continue the drug or switch to placebo. The withdrawal group regained the majority of their lost weight within a year, while those who continued maintained their reductions. This established that the weight management effect of tirzepatide requires ongoing use, a finding that is medically relevant for patient expectations and treatment planning.

The SURPASS-CVOT trial enrolled adults with obesity and established cardiovascular disease and randomized them to tirzepatide or placebo over a median of 3.4 years. The tirzepatide group showed a statistically significant reduction in major adverse cardiovascular events (MACE), a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. This outcome placed tirzepatide alongside semaglutide in having demonstrated cardiovascular risk reduction in a prospective outcome trial.

Long-term metabolic and cardiometabolic effects

Beyond body weight, tirzepatide produced durable improvements across a range of cardiometabolic markers in the trials:

• Blood pressure: Systolic blood pressure reductions of approximately 6 to 8 mmHg were observed in the SURMOUNT trials, attributable to both weight loss and possible direct vascular effects.
• Triglycerides and lipids: Triglyceride reductions and improvements in HDL cholesterol were consistent across the SURPASS program, paralleling the changes expected from significant adiposity reduction.
• Insulin sensitivity and glucose regulation: Improvements in fasting glucose, hemoglobin A1c, and insulin sensitivity were pronounced, consistent with what would be expected from the combined GLP-1 and GIP receptor activity and from weight loss itself.
• Inflammatory markers: Reductions in high-sensitivity C-reactive protein (hsCRP), a marker of systemic inflammation, were reported in several SURPASS substudies. This may reflect the metabolic consequences of fat mass reduction rather than a direct anti-inflammatory mechanism, though research is ongoing.

Lean mass and muscle: a key long-term consideration

One of the most practically important long-term questions about tirzepatide concerns body composition. Significant rapid weight loss from any cause results in some loss of lean mass alongside fat mass. The proportion of lean mass lost depends on protein intake, resistance training, and the rate of weight loss.

SURMOUNT-1 body composition substudies found that roughly 25 to 40% of total weight lost on tirzepatide came from lean mass (including muscle and other non-fat tissue), with the remainder from fat mass. This proportion is similar to what is observed with other effective weight loss interventions.

For people considering long-term tirzepatide use, muscle preservation matters for long-term metabolic health, functional capacity, and body composition quality. The primary tools for preserving lean mass during extended tirzepatide therapy are:

• Maintaining protein intake at a minimum of 0.7 to 1.0 g per pound of target body weight daily, even when appetite is suppressed.
• Consistent resistance training, even at moderate volume, to provide a muscle-preserving signal during the caloric deficit period.
• Discussing dose management with your clinician if weight loss is proceeding faster than lean mass can be preserved.

Thyroid and pancreatic safety: what the data shows

Two long-term safety questions receive the most attention in GLP-1 class literature: thyroid C-cell effects and pancreatitis risk.

Thyroid C-cell effects

GLP-1 receptor agonists caused C-cell hyperplasia and medullary thyroid carcinoma (MTC) in rodent studies at exposures well above human therapeutic levels. This finding is the basis for the black box warning in the class. However, rodent C-cells have a much higher density of GLP-1 receptors than human C-cells, and the pharmacological context differs significantly between species. To date, the multi-year human epidemiological data and clinical trial adverse event profiles have not shown an elevated MTC risk in people on GLP-1 or GIP/GLP-1 agonists at therapeutic doses.

Tirzepatide remains contraindicated in individuals with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Clinician screening for this history is a standard part of any appropriate intake evaluation.

Pancreatitis

Acute pancreatitis has been reported in people taking GLP-1 receptor agonists. The incidence in large randomized trials is low and not consistently higher than placebo groups, but it is a recognized adverse event that requires clinical awareness. Individuals with a history of pancreatitis or significant alcohol use require careful evaluation before starting any GLP-1 class medication.

What are the open questions about tirzepatide’s long-term safety?

Honesty about the limits of the current evidence matters for long-term planning:

• Beyond three years: Most of the tirzepatide RCT data available as of mid-2026 covers up to 72 to 88 weeks of treatment. The SURPASS-CVOT extends to 3.4 years for the cardiovascular primary endpoint, but safety surveillance and long-term registry data for decade-long use is still accumulating.
• Effects in younger healthy adults: The pivotal trials enrolled adults with obesity and significant metabolic comorbidities. Long-term data for metabolically healthier individuals using tirzepatide primarily for body composition optimization is less robust.
• Compounded formulation parity: The long-term trial data was generated using pharmaceutical-grade tirzepatide from controlled manufacturing. Compounded tirzepatide prepared by licensed 503A pharmacies from pharmaceutical-grade active ingredient is intended to deliver the same molecule, but independent long-term registry data on compounded formulations is limited.

Frequently asked questions